Scholarlink

Background and objective <p>Central Nervous System (CNS) tumors are the leading solid malignancies in children, 50% of CNS tumors in children are glial tumors, with two-thirds of these gliomas being categorized as low-grade gliomas (LGG). We aimed to review the clinical profile, management, and outcomes of pediatric LGG cases.</p> Methodology <p>A retrospective cohort study was conducted at Aga Khan University Hospital between 2013 and 2025 including patients aged ≤ 18 years diagnosed with LGG.</p> Results <p>A total of 191 patients were identified, with a slight preponderance of male patients (51.3%). Median age was 10 years (IQR 6–14) with the larger age group being 10–18 years (50.3%). Median duration of presenting symptoms was 4 months (IQR 1–18). Headaches (<i>n</i> = 112, 58.6%) and vomiting (<i>n</i> = 93, 48.7%) were the primary presenting complaints. Tumors were predominantly supratentorial (<i>n</i> = 115, 60.2%). The most common histopathology was Pilocytic Astrocytoma (<i>n</i> = 119). Upfront surgery was done in 163 (85.3%) patients; Gross Total Resection (GTR) was achieved in 85 patients (52.1%). Twenty-six (13.7%) patients received Chemotherapy while 9 (4.8%) had radiation therapy. Disease didn’t progress in 131 (68.6%) patients while progression and relapse occurred in 36 (18.8%) and 7 (3.7%) patients, respectively. Seventeen (8.9%) patients did not have any follow-op scans. The Overall Survival (OS) was 95.3%, with only 9 deaths recorded. Biopsy was deferred to 28 patients (14.7%), a group primarily comprising Subependymal Giant Cell Astrocytomas (SEGA) (<i>n</i> = 17, 60.7%), Tectal Plate Glioma (<i>n</i> = 3, 10.7%), and Optic Path Glioma (<i>n</i> = 5, 17.8%). Kaplan-Meier analysis estimated a median EFS of 84.2 months (95% CI: 70.9–97.5 months). However, this estimate should be interpreted cautiously given the relatively short median follow-up and substantial right-censoring.</p> Conclusion <p>Despite heterogeneity in histopathology and location, outcomes were comparable to those reported in the literature, underscoring the effectiveness of current practices while highlighting the need for improved follow-up and comprehensive outcome reporting in resource-limited settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pediatric low-grade gliomas; a 12-year retrospective review from a tertiary care hospital in LMIC

  • 期刊论文

  • 发表日期：

    2026年5月13日

查看全文
  • Naureen Mushtaq,
  • Farrah Bashir,
  • Soha Zahid,
  • Muhammad Ashir Shafique,
  • Muhammad Mobeen Shahid,
  • Abdul Rehman,
  • Khurram Minhas,
  • Shayan Sirat Maheen Anwar,
  • Bilal Mazhar Qureshi,
  • Syed Ather Enam,
  • Uri Tabori,
  • Eric Bouffet

摘要

Background and objective

Central Nervous System (CNS) tumors are the leading solid malignancies in children, 50% of CNS tumors in children are glial tumors, with two-thirds of these gliomas being categorized as low-grade gliomas (LGG). We aimed to review the clinical profile, management, and outcomes of pediatric LGG cases.

Methodology

A retrospective cohort study was conducted at Aga Khan University Hospital between 2013 and 2025 including patients aged ≤ 18 years diagnosed with LGG.

Results

A total of 191 patients were identified, with a slight preponderance of male patients (51.3%). Median age was 10 years (IQR 6–14) with the larger age group being 10–18 years (50.3%). Median duration of presenting symptoms was 4 months (IQR 1–18). Headaches (n = 112, 58.6%) and vomiting (n = 93, 48.7%) were the primary presenting complaints. Tumors were predominantly supratentorial (n = 115, 60.2%). The most common histopathology was Pilocytic Astrocytoma (n = 119). Upfront surgery was done in 163 (85.3%) patients; Gross Total Resection (GTR) was achieved in 85 patients (52.1%). Twenty-six (13.7%) patients received Chemotherapy while 9 (4.8%) had radiation therapy. Disease didn’t progress in 131 (68.6%) patients while progression and relapse occurred in 36 (18.8%) and 7 (3.7%) patients, respectively. Seventeen (8.9%) patients did not have any follow-op scans. The Overall Survival (OS) was 95.3%, with only 9 deaths recorded. Biopsy was deferred to 28 patients (14.7%), a group primarily comprising Subependymal Giant Cell Astrocytomas (SEGA) (n = 17, 60.7%), Tectal Plate Glioma (n = 3, 10.7%), and Optic Path Glioma (n = 5, 17.8%). Kaplan-Meier analysis estimated a median EFS of 84.2 months (95% CI: 70.9–97.5 months). However, this estimate should be interpreted cautiously given the relatively short median follow-up and substantial right-censoring.

Conclusion

Despite heterogeneity in histopathology and location, outcomes were comparable to those reported in the literature, underscoring the effectiveness of current practices while highlighting the need for improved follow-up and comprehensive outcome reporting in resource-limited settings.